Home > Haematology > ASH 2020 > Multiple Myeloma > Deep and durable responses with ide-cel in RRMM

Deep and durable responses with ide-cel in RRMM

Presented By
Dr Yi Lin, Mayo Clinic, Minnesota, USA
ASH 2020
Phase 1, CRB-401
Updated results from the CRB-401 study demonstrated deep and durable responses with idecabtagene vicleucel (ide-cel), in heavily pretreated patients with relapsed and/or refractory multiple myeloma (R/R MM). In this highly triple-class-exposed population, median overall survival (OS) was 34.2 months and half of ongoing responders achieved duration of response (DOR) >2 years [1]. Patients with R/R MM previously exposed to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies have poor outcomes with subsequent regimes. Deep and durable responses are uncommon, median progression-free survival (PFS) is 2-6 months, and median OS is <12 months. Ide-cel, a B-cell maturation antigen (BCMA)-directed chimaeric antigen receptor (CAR) T-cell therapy, demonstrated tolerability and promising efficacy in patients with R/R MM in the first-in-human phase 1 CRB-401 study (

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on